AstraZeneca Stock Rises 10% Following Tariff Announcement Is AstraZeneca a Good Investment?

Shares of AstraZeneca (NASDAQ: AZN) surged over 10% this week following positive clinical results for Enhertu in HER2-positive breast cancer and a significant deal between Pfizer (NYSE: PFE) and the Trump administration, where Pfizer will reduce drug prices and invest $70 billion domestically, gaining a three-year exemption from tariffs on pharmaceutical imports. This agreement was highlighted during a press conference with Pfizer CEO Albert Bourla and President Trump.

Want More Context? 🔎